Case Study: Reimbursement Strategy for Lifesaving Cervical Dilator
Case Studies
Devices
Due Diligence
Commercial Contracting Process, Evaluations, and Metrics
Payer/KOL P&R Input to New Oncology Biologic Development Plan
Launch Planning and Implementation Support for Novel Biologic
Federal And State Policy
Case Study: Medicare Part D Liability Model
Case Study: Understanding the Impact of the MFPs for IPAY 2026
Case Study: Strengthening Positioning for IRA Drug Price Negotiation
Case Study: Demystifying the Evolving Policy Landscape for Oncology
Case Study: Navigating the Inflation Reduction Act
Evaluation of Biosimilar Utilization by Hospital Types
Advocacy Coalition for Uptake of Comprehensive Genomic Profiling
Physician State Society Federal and State Policy Counsel
Community Oncology Practice Federal and State Policy Counsel
Biopharmaceutical Policy Analysis and Advocacy Strategy
Medicaid Reimbursement Landscape Analysis
Self-Administered Drug Exclusion List
Most Favored Nation (MFN) Model
Insulin Coverage and Affordability
Mental Health Drug
Novel Treatment for Rare Pediatric Genetic Disorder
Medicare Home Infusion Therapy Benefit
Medicare Part D Benefit Redesign
“Government Negotiation” of Drug Prices
White Paper Development on Policy Landscape for Bio/Pharma Industry
Secure Channel Relationships
Medicare Coverage
AMCP Advisory Board
Market Access
Case Study: Parkinson’s Cell and Gene Therapy: Commercialization Strategy Workshop
Case Study: CMMI Engagement on CGT Model
Case Study: Product Ideation and Commercialization Strategies
Case Study: Novel Car T-Cell Reimbursement and Positioning Strategy
Case Study: Uncovering Potential for Products with Clinical, Epidemiology, and Real-World Cost Benefits
Case Study: Medical Policy Influencers Stakeholder Mapping
Type 2 Diabetes Digital Therapeutics Reimbursement Strategy
Product Positioning for a Novel Cancer Therapy
Launch Roadmap for a Novel Vaccine
Value Based Payment for Gene Therapy
Metastatic Melanoma Cell Therapy Launch
U.S. Respiratory Syncytial Virus (RSV) Vaccine
Gene Therapy Pricing
Cell Therapy Pricing
Pharma ELTs
Rare and Ultra Rare Therapeutics
U.S. Launch of a Ex-U.S. Oncology Agent
Physician-Administered Drug Commercialization
Next-Generation Sequencing-Based Multi-Cancer Panel
Liquid Biopsy Assay
Novel International Molecular Diagnostic System
Prostate Cancer Prognostic Assay
Evaluation and Strategic Planning for Combination Pricing
Value/Price Message Development for Executive Team
Evaluation of Indication-Based Pricing for Oncology Biologic
Demonstrate Value to Payers
Segmentation and Understanding Payers
Pharmaceuticals and Biotech
Reimbursement
Case Study: Reimbursement Strategy for Lifesaving Cervical Dilator
Occupational Therapy, Valuation of New Assessment Codes
Remote Therapeutic Monitoring
Cardiovascular Technologies
Lumbar Spine Stenosis Device
Non-Opioid Device Pain Relief Product
AI Device for Osteoporosis Assessment
Osseochondral Knee Implant
Wound Product
Diabetic Devices and Supplies
Commercial Strategy for Orphan Disease Commercial Strategy
Part A and Part B Drug Codes
Alzheimer’s Diagnostic and Drug
Pharmacogenomic Panel
Osteoarthritis Pain Drug
Colorectal Cancer Screening Test
Minimal Residual Disease Test
Payer Reimbursement Landscape
CPT Coding
HCPCS Coding
Payer Workshops on Clinical Endpoints and P&R for Novel Biologic
Strategic Analytics, Value and Economics
Case Study: Medicare Part D Liability Model
Case Study: Medicare Utilization and Cost Trends for CAR-T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma
Case Study: Assessing PD-1/PD-L1 Usage in the Enhancing Oncology Model
Case Study: Patient Population Analysis
Retrospective Study: SGLT-2 Inhibitors Rx Disparities and Affordability Among Medicare Patients with Diabetes
Assessing the Hypertension Market in Medicare and Medicaid Populations
Go-to-Market Strategy Development and Execution for Progyny
Strategic Planning for Part B Launch
Strategic Partnerships for Digital Health Clients
Device Concept, Creation, and Commercialization